Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitiglinide/voglibose vs low-dose glimepiride on endothelial function and glycemic variability in type 2 diabetes
jRCTs071190047Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of mitiglinide, voglibose and glimepiride in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Reactive hyperemia index (RHI) and Mean amplitude of glycemic excursions (MAGE). Started Feb 2021; status: completed.
02
Drugs
mitiglinidevogliboseglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs071190047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190047.